Sec Form 3 Filing - SEIDENBERG BETH C @ Sagimet Biosciences Inc. - 2023-07-13

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person SEIDENBERG BETH C 2. Issuer Name and Ticker or Trading Symbol Sagimet Biosciences Inc. [ SGMT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) SAGIMET BIOSCIENCES INC., 155 BOVET ROAD, SUITE 303 3. Date of Earliest Transaction (MM/DD/YY) 07/13/2023 (Street) SAN MATEO,, CA94402 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 38,763 I See footnote ( 1 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 6,781 I See footnote ( 1 ) Series B Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 6,208 I See footnote ( 1 ) Series B-1 Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 108,163 I See footnote ( 1 ) Series C Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 108,163 I See footnote ( 1 ) Series D Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 76,796 I See footnote ( 1 ) Series E Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 84,768 D ( 3 ) Series E Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 1,297,549 I See footnote ( 1 ) Series F Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 257,052 I See footnote ( 1 ) Stock Option (Right to Buy) $ 6.36 ( 4 ) 04/28/2029 Common Stock 23,216 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other SEIDENBERG BETH C SAGIMET BIOSCIENCES INC. 155 BOVET ROAD, SUITE 303 SAN MATEO,, CA94402 X Signatures /s/ Dennis Hom, Attorney-in-Fact 07/13/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC ("KPCB PBD"). The managing member of KPCB PBD is KPCB PBD Associates, LLC ("KPCB PBD Associates"). All securities are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. ( 2 )Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a 79.4784-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock effected by the Issuer on July 7, 2023) at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering into the number of shares shown in column 3. The Preferred Stock has no expiration date. ( 3 )Shares held directly by the Reporting Person. Such shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". ( 4 )The shares underlying this option are fully vested and exercisable as of the date hereof.

Remarks: Exhibit 24 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.